Trial shows aspirin doesn’t help protect Type 2 diabetes patients from heart disease
CHICAGO A trial published last week in the Journal of the American Medical Association determined that low-dose aspirin as a primary prevention tool against heart disease was ineffective in patients with Type 2 diabetes.
The study followed 2,539 Japanese patients diagnosed with Type 2 diabetes from December 2002 through April 2008 who had no prior incidence of heart disease. A total of 68 heart-disease events occurred in the group taking low-dose aspirin, vs. 86 events among those not taking any aspirin therapy.
Accordingly, the authors of the study concluded that in patients with Type 2 diabetes, low-dose aspirin as a primary prevention did not reduce the risk of cardiovascular events.
The Center for Drug Evaluation and Research, in a consumer education post on its web site, states that low-dose aspirin has been shown to be helpful when used daily to lower the risk of heart attack, clot-related strokes and other blood flow problems, so long as consumers consult a healthcare professional to talk about the use of low-dose aspirin on a daily basis.
Homeolab approaches children’s cough-cold market with addition of Kids 0-9
BUFFALO, N.Y. Homeopathic manufactuer Homeolab USA is taking a direct shot at all the consternation surrounding kids cough-cold this season with the launch of a new line of cough and cold products branded Kids 0-9, that, as its brand name suggests, is recommended for use in children under one year through age nine.
“The Consumer Healthcare Products Association’s announcement last month that allopathic medicines should not be used for children under the age of four has left parents scrambling for other options to treat their children during this years cough and cold season,” the company stated in a press release issued Friday. “Homeolab USA offers a safe alternative with their Kids 0-9 cough and cold syrup, an all-natural homeopathic formula that helps eliminate symptoms associated with a cold by getting to the source of the problem.”
In addition to Cough & Cold, the product line includes formulas for colic, earache, teething and calm.
Nielsen report shows more consumers switching to private label products
SCHAUMBURG, Ill. Once considered a lower-price, lower-quality substitute for name brands, private label products, or store brands, are viewed positively by the majority of U.S. consumers, according to a new survey by The Nielsen Company. As many as 72 percent of consumers believe store brands are good alternatives to name brands and 62 percent of consumers report they consider store brands to be as good as name brands, up three points since 2005.
“While private label products continue to follow the success of consumer packaged goods manufacturers’ name brand introductions, more CPG retailers are making private label a priority with messages on quality as strong as messages on value,” said Todd Hale, senior vice president of Consumer & Shopper Insights for the Nielsen Company.
According to Nielsen’s survey, price and value are paramount, especially in today’s market. Three out of four consumers believed it is important to get the best price on a product. More than two-thirds 67 percent) of consumers agreed that store brands usually provide “extremely good value” for the money while 35 percent of consumers are willing to pay the same or more for store brands if they like it.
Conversely, only one out of every four consumers believed that name brand products are worth the extra price. “In today’s economy, consumers are looking for ways to save money and for many of them, that means taking a new look at private label products,” Hale said. “With more retailers offering satisfaction guarantees on private label purchases and even serving up blind taste testing and trial programs, consumers’ exposure to private label products has never been greater.”
Private label products account for more than $81 billion in the United States, up 10.2 percent over the past year, Nielsen reported.